ArticleThe Kaohsiung journal of medical sciences2025
LncRNA SOX21-AS1 Promotes the Progression of Pancreatic Cancer by Sponging miR-9-3p and Upregulating YOD1.
Article in The Kaohsiung journal of medical sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- LncRNA SOX21-AS1 Promotes the Progression of Pancreatic Cancer by Sponging miR-9-3p and Upregulating YOD1.The Kaohsiung journal of medical sciences · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pancreatic cancer (PC) is a highly aggressive malignancy of the digestive system. Recent studies have indicated that the long noncoding RNA SOX21-AS1 is significantly upregulated in PC tissue samples. This study aims to elucidate the biological role and underlying molecular mechanisms of SOX21-AS1 in PC progression. Quantitative real-time PCR (qRT-PCR) and western blot analyses were employed to assess RNA and protein expression levels, respectively. The subcellular localization of SOX21-AS1 was determined using subcellular fractionation assays. PC cell viability, migratory capacity, and apoptosis were evaluated through CCK-8 assays, wound healing assays, and flow cytometry. Dual-luciferase reporter and RNA pull-down assays were conducted to confirm the interactions between miR-9-3p and either SOX21-AS1 or YOD1. Additionally, a xenograft mouse model was established to investigate the in vivo effects of SOX21-AS1. The findings revealed that SOX21-AS1 is highly expressed in PC tissues and cell lines, with its upregulation correlating with poor patient prognosis. Functional assays demonstrated that knockdown of SOX21-AS1 suppressed PC cell proliferation and migration, induced apoptosis in vitro, and reduced tumor growth in vivo. Mechanistically, SOX21-AS1 competitively interacted with miR-9-3p to upregulate YOD1, consequently activating the TGF-β/Smad signaling pathway. Furthermore, overexpression of YOD1 reversed the tumor-suppressive effects observed after SOX21-AS1 knockdown. In conclusion, SOX21-AS1 promotes PC cell malignancy through the miR-9-3p/YOD1 axis and subsequent activation of TGF-β/Smad signaling.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.